{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["20(8)"],"submitter":["Gow CH"],"pubmed_abstract":["A kinesin family member 5b (KIF5B)-MET proto-oncogene, receptor tyrosine kinase (MET) rearrangement was reported in patients with lung adenocarcinoma but its oncogenic function was not fully evaluated. We used one-step reverse transcription-polymerase chain reaction for RNA samples to screen for the KIF5B-MET fusion in 206 lung adenocarcinoma and 28 pulmonary sarcomatoid carcinoma patients. Genomic breakpoints of KIF5B-MET were determined by targeted next-generation sequencing. Soft agar colony formation assays, proliferation assays, and a xenograft mouse model were used to investigate its oncogenic activity. In addition, specific MET inhibitors were administered to evaluate their anti-tumor activities. A KIF5B-MET fusion variant in a patient with a mixed-type adenocarcinoma and sarcomatoi"],"journal":["Neoplasia (New York, N.Y.)"],"pagination":["838-847"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6068088"],"repository":["biostudies-literature"],"pubmed_title":["Oncogenic Function of a KIF5B-MET Fusion Variant in Non-Small Cell Lung Cancer."],"pmcid":["PMC6068088"],"pubmed_authors":["Liu YN","Tsai TH","Chen PL","Hsieh MS","Chang SH","Li HY","Gow CH","Tsai MF","Luo SC","Shih JY"],"additional_accession":[]},"is_claimable":false,"name":"Oncogenic Function of a KIF5B-MET Fusion Variant in Non-Small Cell Lung Cancer.","description":"A kinesin family member 5b (KIF5B)-MET proto-oncogene, receptor tyrosine kinase (MET) rearrangement was reported in patients with lung adenocarcinoma but its oncogenic function was not fully evaluated. We used one-step reverse transcription-polymerase chain reaction for RNA samples to screen for the KIF5B-MET fusion in 206 lung adenocarcinoma and 28 pulmonary sarcomatoid carcinoma patients. Genomic breakpoints of KIF5B-MET were determined by targeted next-generation sequencing. Soft agar colony formation assays, proliferation assays, and a xenograft mouse model were used to investigate its oncogenic activity. In addition, specific MET inhibitors were administered to evaluate their anti-tumor activities. A KIF5B-MET fusion variant in a patient with a mixed-type adenocarcinoma and sarcomatoi","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Aug","modification":"2025-04-04T20:30:45.843Z","creation":"2019-03-26T23:49:11Z"},"accession":"S-EPMC6068088","cross_references":{"pubmed":["30015159"],"doi":["10.1016/j.neo.2018.06.007"]}}